BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/14/2021 7:32:38 AM | Browse: 797 | Download: 1904
 |
Received |
|
2021-01-21 10:26 |
|
Peer-Review Started |
|
2021-01-21 10:26 |
|
First Decision by Editorial Office Director |
|
2021-02-09 18:38 |
|
Return for Revision |
|
2021-02-09 18:38 |
|
Revised |
|
2021-02-17 00:38 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-03-12 14:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-03-13 06:45 |
|
Articles in Press |
|
2021-03-13 06:45 |
|
Edit the Manuscript by Language Editor |
|
2021-03-29 02:37 |
|
Typeset the Manuscript |
|
2021-04-13 00:12 |
|
Publish the Manuscript Online |
|
2021-04-14 07:32 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Abelson interactor 1 splice isoform-L plays an anti-oncogenic role in colorectal carcinoma through interactions with WAVE2 and full-length Abelson interactor 1
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kun Li, Yi-Fan Peng, Jing-Zhu Guo, Mei Li, Yu Zhang, Jing-Yi Chen, Ting-Ru Lin, Xin Yu and Wei-Dong Yu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
30872923 |
| National Natural Science Foundation of China |
81672853 |
| Peking University People’s Hospital Scientific Research Development Found |
RDH2020-11 |
|
| Corresponding Author |
Wei-Dong Yu, PhD, Professor, Department of Central Laboratory and Institute of Clinical Molecular Biology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China. weidongyu@bjmu.edu.cn |
| Key Words |
Colon cancer; Abelson interactor 1 isoform-L; Cell adhesion; Cell migration; WAVE2 |
| Core Tip |
The purpose of this study was to investigate the role and mechanism of Abelson interactor 1 splice isoform-L (ABI1-SiL) in the metastatic behavior of colorectal carcinoma cells. Our results showed that ABI1-SiL played a key role in cell surface area, adhesion, and migration, but not proliferation and apoptosis in SW480 cells. ABI1-SiL may have anti-oncogenic roles by competitively binding to WAVE2, and directly interacting with phosphorylated and non-phosphorylated ABI1-p65, functioning as a dominant-negative molecule towards ABI1-p65. |
| Publish Date |
2021-04-14 07:32 |
| Citation |
Li K, Peng YF, Guo JZ, Li M, Zhang Y, Chen JY, Lin TR, Yu X, Yu WD. Abelson interactor 1 splice isoform-L plays an anti-oncogenic role in colorectal carcinoma through interactions with WAVE2 and full-length Abelson interactor 1. World J Gastroenterol 2021; 27(15): 1595-1615 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i15/1595.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i15.1595 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
